Literature DB >> 3408634

Concentration-effect relationships for oxprenolol in patients with essential hypertension.

G T McInnes1, M J Brodie.   

Abstract

1. Plasma drug concentrations, and heart rate and blood pressure responses to exercise at a predetermined load were examined in twelve hypertensive patients following single and repeated doses of oxprenolol administered once daily as oral osmotic drug delivery systems (10/170 and 16/260 oxprenolol OROS). 2. Plasma oxprenolol concentration profiles after each preparation were consistent with the criteria for sustained drug release. Levels immediately after exercise were significantly higher than those prior to exercise (P less than 0.001), but differences were slight. 3. Both OROS drug forms reduced exercise heart rate for 24 h after single and repeated doses; effects were greater for 16/260 OROS than for 10/170 OROS. Significant reductions in post-exercise systolic BP were observed 24 h after drug administration and after repeated doses there was little difference between the preparations. Effects on diastolic BP after exercise were slight. 4. The relationship between plasma oxprenolol concentrations and exercise heart rates fitted an exponential mathematical model which makes allowance for inter-individual variability. No such kinetic-dynamic relationship could be defined for post-exercise systolic or diastolic BP.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3408634      PMCID: PMC1386426          DOI: 10.1111/j.1365-2125.1988.tb03343.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  25 in total

1.  Simplified method for the determination of oxprenolol and other beta-receptor-blocking agents in biological fluids by gas-liquid chromatography.

Authors:  P H Degen; W Riess
Journal:  J Chromatogr       Date:  1976-06-09

2.  Elementary osmotic pump.

Authors:  F Theeuwes
Journal:  J Pharm Sci       Date:  1975-12       Impact factor: 3.534

3.  Pharmacokinetics of oxprenolol in normal subjects.

Authors:  W D Mason; N Winer
Journal:  Clin Pharmacol Ther       Date:  1976-10       Impact factor: 6.875

4.  The effect on blood pressure of beta-adrenoceptor blocking drugs administered once daily and their duration of action when therapy is ceased.

Authors:  M Wilson; G Morgan; T Morgan
Journal:  Br J Clin Pharmacol       Date:  1976-10       Impact factor: 4.335

5.  Control of heart rate by the autonomic nervous system. Studies in man on the interrelation between baroreceptor mechanisms and exercise.

Authors:  B F Robinson; S E Epstein; G D Beiser; E Braunwald
Journal:  Circ Res       Date:  1966-08       Impact factor: 17.367

6.  The use of drug concentration measurements in studies of the therapeutic response to propranolol.

Authors:  C Chidsey; M Pine; L Favrot; S Smith; G Leonetti; P Morselli; A Zanchetti
Journal:  Postgrad Med J       Date:  1976       Impact factor: 2.401

7.  Pharmacokinetics and pharmacodynamics of alprenolol in the treatment of hypertension. II. Relationship to its effect on blood pressure and plasma renin activity.

Authors:  P Collste; K Haglund; M Frisk-Holmberg; M L Orme; M D Rawlins; J Ostman
Journal:  Eur J Clin Pharmacol       Date:  1976-06-15       Impact factor: 2.953

8.  Relation between plasma concentrations and cardiovascular effects of oral oxprenolol in man.

Authors:  L Brunner; P Imhof; D Jack
Journal:  Eur J Clin Pharmacol       Date:  1975       Impact factor: 2.953

9.  Osmotic delivery systems for the beta-adrenoceptor antagonists metoprolol and oxprenolol: design and evaluation of systems for once-daily administration.

Authors:  F Theeuwes; D R Swanson; G Guittard; A Ayer; S Khanna
Journal:  Br J Clin Pharmacol       Date:  1985       Impact factor: 4.335

10.  Pathophysiologic and pharmacokinetic determinants of the antihypertensive response to propranolol.

Authors:  M Esler; A Zweifler; O Randall; V DeQuattro
Journal:  Clin Pharmacol Ther       Date:  1977-09       Impact factor: 6.875

View more
  2 in total

Review 1.  Influence of exercise on the pharmacokinetics of drugs.

Authors:  M A van Baak
Journal:  Clin Pharmacokinet       Date:  1990-07       Impact factor: 6.447

2.  CNS-related performance and haemodynamics of metoprolol-Oros and propranolol after single and 3 days dosing in healthy volunteers.

Authors:  A L van Steveninck; M S Pieters; H C Schoemaker; D D Breimer; A F Cohen
Journal:  Br J Clin Pharmacol       Date:  1993-02       Impact factor: 4.335

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.